Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 17/20 | 0.64 |
| ▸ | VEGFA | P15692 | 6/20 | 0.64 |
| ▸ | FLT1 | P17948 | 6/20 | 0.64 |
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 0.64 |
| ▸ | TET3 | O43151 | 1/20 | 0.58 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.58 |
| ▸ | ASPH | Q12797 | 1/20 | 0.58 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.58 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.58 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.58 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.58 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.58 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19933514 | 0.90 | EGLN1 (0.72) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL19933469 | 0.88 | EGLN1 (0.82) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL19933511 | 0.88 | EGLN1 (0.57) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL19933453 | 0.84 | EGLN1 (0.66) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL24579666 | 0.83 | EGLN1 (0.78) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL30790421 | 0.83 | EGLN1 (0.78) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL19933411 | 0.83 | EGLN1 (0.60) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL29188896 | 0.82 | EGLN1 (0.75) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL19933379 | 0.80 | VEGFA (0.44) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL21565675 | 0.79 | EGLN1 (0.71) | EGLN1VEGFAFLT1EGLN3TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180065933-A1 | DEUTERIUM-ENRICHED HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE ENZYME INHIBITORS | AKEBIA THERAPEUTICS, INC. (US) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065933-A1 | DEUTERIUM-ENRICHED HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE ENZYME INHIBITORS | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885VEGFA 286/4885FLT1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.